Non Small Cell Lung Cancer Clinical Trial
Official title:
A Phase I Dose Defining Study For MK-2206 Combined With Gefitinib In NSCLC Population Enriched With EGFR Mutation
This is a phase I study of MK2206 (an AKT inhibitor)and gefitinib in nonsmall cell lung
cancer patients who failed prior chemotherapy and epidermal growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI). The patient population is enriched for EGFR mutations.
The purpose of this study is to determine whether it is safe to administered MK-2206 in
combination with gefitinib in adult patients with locally advanced or metastatic non-small
cell lung cancer. The second purpose of this study is to define the MTD (Maximum Tolerated
Dose) of MK-2206 when combined with gefitinib.
A standard 3-3 dose escalation scheme of MK-2206 with fix dose gefitinib is used in this
study.
Preclinical data from communication with Merck clinical and pre-clinical group support the
application of MK2206 and an EGFR-TKI, and the synergistic effect of this combination. This
proposed study is a phase I dose defining study to define the MTD (Maximum Tolerated Dose) of
MK-2206 when combined with gefitinib.
MK-2206 is a potent, orally active, allosteric inhibitor of human AKT1, AKT2, and AKT3 with
preclinical anti-tumor activity.
This is a Phase I, single-center, open-label, non-randomized, dose-escalation study in
patients with locally advanced or metastatic NSCLC. Patients who previously failed and
progressed through EGFR inhibitor such as erlotinib or gefitinib and up to one line of
chemotherapy will be enrolled into the study. Patients will be administered with oral MK-2206
and a standard dose of EGFR inhibitor gefitinib.
This study will be conducted in three cohorts to identify a recommended Phase II dose (RP2D)
of MK-2206 in combination with standard dose of gefitinib (250 mg QD). Cohorts of 3 patients
will be enrolled sequentially on escalating doses of MK-2206 administered in combination with
a standard dose of gefitinib. Patients will advance doses of MK2206 if 0/3 patients or 0-1/6
develop DLT (Dose-Limiting Toxicity). If 1/3 patient develops DLT, the cohort will be
expanded to 6. If 2/6 patients developed DLT, the dose will be de-escalate to 90 mg Qwk. The
highest dose cohort with 0-1/6 with DLT will be deemed as MTD and used as cohort expansion
for a total of 15 patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
| Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
| Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
| Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
| Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
| Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
| Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
| Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
| Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
| Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
| Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 |